Literature DB >> 28008350

Safety profile of lamotrigine in overdose.

Akintunde Alabi1, Adam Todd2, Andrew Husband2, Joe Reilly3.   

Abstract

BACKGROUND: Lamotrigine is an anticonvulsant as well as a mood stabilizer. Apart from its established use in the treatment of epilepsy, there has been an expansion of its use in the treatment of mental disorders. Patients with epilepsy as well as those with mental disorders are at increased risk of deliberate drug overdoses. An evidence base for the safety profile of lamotrigine in overdose is an essential tool for prescribers. The objective of this study was to carry out a narrative synthesis of the existing evidence for the safety profile of lamotrigine in overdose.
METHODS: A systematic search was conducted of EMBASE (1974 to December 2015), MEDLINE (1946 to December 2015), PsycINFO (1806 to December 2015) and CINAHL (1981 to December 2015) databases. Studies were included in which there was a deliberate or accidental single drug overdose of lamotrigine, with its toxic effects described. Studies that did not involve an overdose were excluded. A narrative synthesis of the described toxic effects was carried out.
RESULTS: Out of 562 articles identified, 26 studies were included, mainly in the form of case reports and series. The most commonly described toxic effects of lamotrigine were on the central nervous system, specifically seizures, movement disorders and reduced consciousness. Other toxic effects included QTc interval and QRS complex prolongations, hypersensitivity reactions, serotonin syndrome as well as rhabdomyolysis possibly due to seizures and/or agitation. Deaths were recorded in two studies, with cardiovascular and neurological toxic effects described.
CONCLUSIONS: Even though lamotrigine has been reported to be well tolerated, there is a risk of toxic effects which can be life threatening in overdose. This needs to be borne in mind when prescribing to patients at an increased risk of deliberate drug overdose.

Entities:  

Keywords:  death; lamotrigine; overdose; safety; toxicity

Year:  2016        PMID: 28008350      PMCID: PMC5167082          DOI: 10.1177/2045125316656707

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  56 in total

Review 1.  International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.

Authors:  William A Catterall; Alan L Goldin; Stephen G Waxman
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

2.  Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats.

Authors:  G L Weinberg; T VadeBoncouer; G A Ramaraju; M F Garcia-Amaro; M J Cwik
Journal:  Anesthesiology       Date:  1998-04       Impact factor: 7.892

Review 3.  Overview of serotonin syndrome.

Authors:  Mohammad M Iqbal; Miles J Basil; Jonathan Kaplan; Md Touhid Iqbal
Journal:  Ann Clin Psychiatry       Date:  2012-11       Impact factor: 1.567

Review 4.  Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.

Authors:  Victor Biton
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

5.  Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.

Authors:  J P Fillastre; A M Taburet; A Fialaire; I Etienne; R Bidault; E Singlas
Journal:  Drugs Exp Clin Res       Date:  1993

6.  Lamotrigine childhood overdose.

Authors:  G Briassoulis; P Kalabalikis; M Tamiolaki; T Hatzis
Journal:  Pediatr Neurol       Date:  1998-09       Impact factor: 3.372

Review 7.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.

Authors:  Donald Bradford Reich; Mary C Zanarini; Katheryn A Bieri
Journal:  Int Clin Psychopharmacol       Date:  2009-09       Impact factor: 1.659

9.  Clinical outcomes in newer anticonvulsant overdose: a poison center observational study.

Authors:  Brandon Wills; Penny Reynolds; Eileen Chu; Christine Murphy; Kirk Cumpston; Paul Stromberg; Rutherfoord Rose
Journal:  J Med Toxicol       Date:  2014-09

10.  Report of Severe Menorrhagia Following the Maximum Amount of Lamotrigine Overdose.

Authors:  Farid Hajiali; Marjan Nassiri-Asl
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

View more
  6 in total

1.  Serotonin Toxicity Following Suicide with Citalopram and Lamotrigine: A Rare Case Report and Literature Review.

Authors:  Gholamali Dorooshi; Shafeajafar Zoofaghari; Rokhsareh Meamar
Journal:  J Res Pharm Pract       Date:  2020-10-08

2.  Successful management of massive lamotrigine extended-release intoxication in a dog.

Authors:  Alexis S McLaine; Page E Yaxley; Anda A Young; Edward S Cooper
Journal:  Clin Case Rep       Date:  2021-12-16

3.  Escitalopram, bupropion, lurasidone, lamotrigine and possible vortioxetine overdose presented with serotonin syndrome and diffuse encephalopathy: A case report.

Authors:  Suthimon Thumtecho; Sorawit Wainipitapong; Suchai Suteparuk
Journal:  Toxicol Rep       Date:  2021-11-06

Review 4.  Lamotrigine and Stevens-Johnson Syndrome Prevention.

Authors:  Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16

5.  The use of intralipid emulsion therapy to treat severe cardiotoxicity secondary to lamotrigine ingestion in a dog.

Authors:  Tara J Bellis; Laura Gibeon
Journal:  Clin Case Rep       Date:  2018-08-30

6.  Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center.

Authors:  Kelly E Wood; Kendra L Palmer; Matthew D Krasowski
Journal:  Toxicol Rep       Date:  2021-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.